The treatment of knee osteoarthritis is still difficult owing to the lack of a disease-limiting medicine and the scarcity of existing therapeutic interventions, which focus mostly on alleviating symptoms rather than addressing the underlying cause of the condition.Tostudy of the effectiveness of colchicine therapy in a group of patients with primary knee osteoarthritis is the focus of our research. Between the months of October 2020 and March 2022, fifty patients were admitted to the Orthopaedic outpatient clinic of the Medical Complex City of Mosul, Iraq. Each patient received a diagnosis of knee osteoarthritis (KOA) based on the standards established by the American College of Rheumatology (ACR). The participants were split into two separate groups after a random selection process. The observation period lasted for a total of sixteen weeks. Colchicine was given to patients in the first group (a total of 25), at a dose of 1 milligram per day, whereas patients in the second group (also a total of 25), received a placebo.At the 16th week of colchicine therapy, patients in Group 1 who received a colchicine treatment demonstrated a statistically significant decrease in their knee indices, as measured by the WOMAC Total 38.58 + 6.7 (P= 0.05), VAS—overall pain 6.82 + 1.63 (P= 0.05), and Doyle Index 4.74 + 1.42 (P=0.003) scores, when compared to the baseline readings. Nevertheless, colchicine medication was well tolerated since no statistically significant difference in adverse events were noted between the colchicine and placebo groups.Our findings, which monitored VAS, Doyle indexalong with WOMAC indices in two groups of KOA patients, reveal that colchicine treatment is more effective than placebo in lowering symptoms of the condition.

Knee Osteoarthritis (KOA), Colchicine, Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Visual Analogue Scale (VAS).